Review Article | Published:

Clostridium difficile infection: new developments in epidemiology and pathogenesis

Nature Reviews Microbiology volume 7, pages 526536 (2009) | Download Citation

Subjects

Abstract

Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.

Key points

  • This article reviews the latest clinical and fundamental research data on the important human pathogen Clostridium difficile.

  • The clinical aspects of C. difficile infection (CDI) that are discussed include description of the disease spectrum and severity, and the signs, symptoms and clinical pathogenesis of CDI. An overview of the available treatment options for CDI is also given, including discussion of the problems associated with each therapeutic approach and new recommendations for treatment based on disease severity and the numbers of recurrences. CDI prevention is also discussed. Prevention methods include preventing acquisition of C. difficile spores by patients (using barrier and cleaning methods) and reducing the risk of symptomatic infection if the organism is encountered, primarily by avoidance of unnecessary use of antimicrobials.

  • The laboratory diagnosis and characterization of C. difficile is also reviewed. The main detection methods and diagnostic tests, including the recent development of molecular testing and two-step diagnostic protocols, are discussed. The main molecular typing techniques used for C. difficile and the importance of antibiotic resistance testing are described.

  • The changing epidemiology of CDI is reviewed. Important changes in the epidemiology of CDI have been observed over the past five years, especially increased infection rates in hospitals, increased disease severity, and increased rates and mortality with patient age. Most of these changes are presumed to be driven by presence of a new epidemic strain, C. difficile BI/NAP1/027. Changes in host populations (human versus animal populations with previous low risk), a possible increase in community associated disease, and new risk factors have also been observed.

  • The known C. difficile virulence factors (TcdA and TcdB) and newly recognized virulence factors and their role in pathogenesis are discussed.

  • The role of antibiotics in the development of CDI is discussed in relation to the susceptibility of C. difficile to antibiotics taken by the patient. The implication of the resistance of C. difficile to the fluoroquinolone class of antibiotics, and fluoroquinolones as an increasing risk factor for CDI, are discussed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin. Infect. Dis. 18 (Suppl. 4), S265–S272 (1994). Exceptional overview of historical studies and the development of recognition of C. difficile as a human pathogen.

  2. 2.

    et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001–2006. Pediatrics 122, 1266–1270 (2008).

  3. 3.

    et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am. J. Obstet. Gynecol. 198, 635.e1–e6 (2008).

  4. 4.

    et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can. Med. Assoc. J. 171, 466–472 (2004).

  5. 5.

    et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442–2449 (2005). Key early study that highlights the transmission, potential risk factors for, and impact of, a new virulent C. difficile clone.

  6. 6.

    et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob. Agents Chemother. 52, 3180–3187 (2008).

  7. 7.

    et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann. Surg. 235, 363–372 (2002). First documentation of the high severity and mortality of CDI, which was subsequently shown to be caused by the C. difficile BI/NAP1/027 strain.

  8. 8.

    et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 13, pii: 18942 (2008).

  9. 9.

    , & Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12 (Suppl. 6), 2–18 (2006).

  10. 10.

    , , & Clostridium difficile surveillance trends, Saxony, Germany. Emerg. Infect. Dis. 14, 691–692 (2008).

  11. 11.

    , & Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997–2005. Infect. Control Hosp. Epidemiol. 29, 887–889 (2008).

  12. 12.

    Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency , (2008).

  13. 13.

    et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433–2441 (2005). First report of the toxin variant C. difficile BI/NAP1/027 in the United States.

  14. 14.

    et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273–280 (2005).

  15. 15.

    et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin. Infect. Dis. 44, 238–244 (2007).

  16. 16.

    et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J. Clin. Microbiol. 46, 431–437 (2008). Updated comparison of typing techniques for C. difficile.

  17. 17.

    et al. Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains. J. Clin. Microbiol. 46, 954–960 (2008).

  18. 18.

    et al. Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. Euro Surveill. 13, pii: 19057 (2008).

  19. 19.

    et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47, 1162–1170 (2008).

  20. 20.

    , , , & Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J. Clin. Microbiol. 46, 2146 (2008).

  21. 21.

    , , , & Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J. Infect. Dis. 169, 127–133 (1994).

  22. 22.

    et al. Severe Clostridium difficile–associated disease in populations previously at low risk — four states. Morb. Mortal. Wkly Rep. 54, 1201–1205 (2005).

  23. 23.

    Centers for Disease Control and Prevention (CDC). Surveillance for community-associated Clostridium difficile--Connecticut, 2006. Morb. Mortal. Wkly Rep. 57, 340–343 (2008).

  24. 24.

    , , , & A case-control study of community-associated Clostridium difficile infection. J. Antimicrob. Chemother. 62, 388–396 (2008).

  25. 25.

    et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).

  26. 26.

    et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).

  27. 27.

    & The distribution of Clostridium difficile in the environment of South Wales. J. Med. Microbiol. 45, 133–137 (1996). Documentation of the high level of environmental contamination by C. difficile.

  28. 28.

    , , & Clostridium difficile in retail ground meat, Canada. Emerg. Infect. Dis. 13, 485–487 (2007).

  29. 29.

    et al. Clostridium difficile in retail meat products, USA, 2007. Emerg. Infect. Dis. 15, 819–821 (2009).

  30. 30.

    et al. Toxinotype V Clostridium difficile in humans and food animals. Emerg. Infect. Dis. 14, 1039–1045 (2008).

  31. 31.

    Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? Clin. Microbiol. Infect. 13, 457–459 (2007).

  32. 32.

    & Clostridium difficile: an important pathogen of food animals. Anaerobe 12, 1–4 (2006).

  33. 33.

    et al. Clostridium difficile PCR ribotypes in calves, Canada. Emerg. Infect. Dis. 12, 1730–1736 (2006).

  34. 34.

    & The comparative pathology of Clostridium difficile-associated disease. Vet. Pathol. 43, 225–240 (2006).

  35. 35.

    , , , & Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J. Clin. Microbiol. 45, 1963–1964 (2007).

  36. 36.

    , , & The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).

  37. 37.

    et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435–438 (2008). Confirmation of the suspected alteration of the normal bacterial flora in patients with recurrent CDI.

  38. 38.

    , , & Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188, 1922–1927 (2003).

  39. 39.

    , , & Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe 9, 91–95 (2003).

  40. 40.

    et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341, 1645–1651 (1999).

  41. 41.

    et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother. 62, 1046–1052 (2008). Evidence for the emergence and local spread of reduced susceptibility of C. difficile to metronidazole, one of only two main options for the treatment of CDI.

  42. 42.

    et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. Microbiol. 46, 3028–3032 (2008).

  43. 43.

    et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52, 2813–2817 (2008).

  44. 44.

    & Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 46 (Suppl. 1), 12–18 (2008).

  45. 45.

    , , & Clostridium difficile associated diarrhoea: how good are nurses at identifying the disease? Age Ageing 31, 487–488 (2002).

  46. 46.

    & Does the nose know? The odiferous diagnosis of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 44, 1142 (2007).

  47. 47.

    Diagnosis of Clostridium difficile-associated diarrhea and odor. Clin. Infect. Dis. 45, 1110 (2007).

  48. 48.

    et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect. Dis. 8, 777–784 (2008). Summary data showing why there are concerns about the accuracy and poor predictive value of toxin detection kits.

  49. 49.

    , , & Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J. Clin. Microbiol. 46, 1996–2001 (2008).

  50. 50.

    et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin. Infect. Dis. 45, 992–998 (2007).

  51. 51.

    et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J. Clin. Microbiol. 44, 1145–1149 (2006).

  52. 52.

    et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am. J. Med. 71, 815–822 (1981).

  53. 53.

    et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2, 1043–1046 (1983).

  54. 54.

    et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).

  55. 55.

    , , & A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45, 302–307 (2007). Reported a prospective, randomized, stratified, blinded trial that revealed the superiority of vancomycin versus metronidazole for the treatment of severe CDI.

  56. 56.

    , , , & Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J. Infect. Dis. 159, 340–343 (1989).

  57. 57.

    , & Relapse versus reinfection with Clostridium difficile. Epidemiol. Infect. 107, 627–635 (1991).

  58. 58.

    , & Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36, 580–585 (2003).

  59. 59.

    et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann. Surg. 245, 267–272 (2007).

  60. 60.

    , , , & Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. Can. Med. Assoc. J. 179, 767–772 (2008).

  61. 61.

    et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis. 38, 640–645 (2004).

  62. 62.

    et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41, 1254–1260 (2005).

  63. 63.

    , , , & Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can. Med. Assoc. J. 171, 33–38 (2004).

  64. 64.

    , , & Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342, 390–397 (2000).

  65. 65.

    , , & Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189–193 (2001).

  66. 66.

    et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136, 1206–1214 (2009).

  67. 67.

    et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nature Genet. 38, 779–786 (2006).

  68. 68.

    & Cytotoxic effects of the Clostridium difficile toxins. Curr. Top. Microbiol. Immunol. 250, 85–96 (2000).

  69. 69.

    & in The Comprehensive Sourcebook of Bacterial Protein Toxins 3rd edn (eds Alouf, J. A. & Popoff, M. R.) 409–429 (Academic Press, Burlington, Massachusetts, USA, 2006).

  70. 70.

    , & Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17, 15R–22R (2007). Overview of our current knowledge of the structural basis of toxin functions.

  71. 71.

    et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J. Clin. Invest. 95, 2004–2011 (1995).

  72. 72.

    Effects of Clostridium difficile toxins on epithelial cell barrier. Ann. NY Acad. Sci. 915, 347–356 (2000).

  73. 73.

    , & Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc. Natl Acad. Sci. USA 103, 14176–14181 (2006).

  74. 74.

    , , & Effects of Clostridium difficile given intragastrically to animals. Infect. Immun. 47, 349–352 (1985).

  75. 75.

    , , , & The ClosTron: a universal gene knock-out system for the genus Clostridium. J. Microbiol. Methods 70, 452–464 (2007).

  76. 76.

    et al. Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176–1179 (2009).

  77. 77.

    , , & Large clostridial cytotoxins — a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol. 4, 375–382 (1996).

  78. 78.

    , , & A novel toxin homologous to large clostridial catotoxins found in culture supernatant of Clostridium perfringens type C. Microbiology 153, 1198–1206 (2007).

  79. 79.

    et al. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375, 500–503 (1995).

  80. 80.

    , , , & gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect. Immun. 76, 2862–2871 (2008).

  81. 81.

    et al. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 446, 415–419 (2007). First description of self-cleavage of bacterial toxins during internalization in the host cell.

  82. 82.

    , , , & Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J. Biol. Chem. 282, 25314–25321 (2007).

  83. 83.

    & Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl Acad. Sci. USA 98, 5844–5849 (2001).

  84. 84.

    , & Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol. Microbiol. 64, 1274–1288 (2007).

  85. 85.

    , & Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J. Med. Microbiol. 50, 613–619 (2001).

  86. 86.

    , , , & Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 181, 29–38 (1996). Description of the chromosomal element that encodes TcdA and TcdB.

  87. 87.

    et al. Revised nomenclature of Clostridium difficile toxins and associated genes. J. Med. Microbiol. 54, 113–117 (2005).

  88. 88.

    Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol. Rev. 2, 541–555 (2008).

  89. 89.

    et al. Transcription analysis of the genes tcdA–E of the pathogenicity locus of Clostridium difficile. Eur. J. Biochem. 244, 735–742 (1997).

  90. 90.

    , , & Clostridium difficile toxin synthesis is negatively regulated by TcdC. J. Med. Microbiol. 57, 685–689 (2008).

  91. 91.

    , & Comparison of the efficacy of ramoplanin vs vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J. Antimicrob. Chemother. 56, 717–725 (2005).

  92. 92.

    , , , & Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob. Agents Chemother. 53, 412–420 (2009).

  93. 93.

    , , & Repression of Clostridium difficile toxin gene expression by CodY. Mol. Microbiol. 66, 206–219 (2007).

  94. 94.

    et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol. Lett. 186, 307–312 (2000).

  95. 95.

    et al. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J. Bacteriol. 189, 7290–7301 (2007).

  96. 96.

    , , , & Production of a complete binary toxin (actin-specific ADP-ribosyltranferase) by Clostridium difficile CD196. Infect. Immun. 65, 1402–1407 (1997).

  97. 97.

    et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J. Infect. Dis. 193, 1143–1150 (2006).

  98. 98.

    & Patterns of sequence conservation in the S-layer proteins and related sequences in Clostridium difficile. J. Bacteriol. 184, 33886–33897 (2002).

  99. 99.

    et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol. Med. Microbiol. 41, 237–242 (2004).

  100. 100.

    et al. Proteomic analysis of cell surface proteins from Clostridium difficile. Proteomics 5, 2443–2452 (2005).

  101. 101.

    , & Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J. Clin. Microbiol. 43, 5018–5025 (2005).

  102. 102.

    et al. Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. Microbes Infect. 8, 2640–2646 (2006).

  103. 103.

    , & in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).

  104. 104.

    et al. Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect. Control Hosp. Epidemiol. 28, 920–925 (2007). Quantification of the activity of detergents and disinfectants against C. difficile and the potential for some of these products to promote sporulation.

  105. 105.

    & Cross-contamination of Clostridium difficile spores on bed linen during laundering. Am. J. Infect. Control 35, E32–E33 (2007).

  106. 106.

    & Hospital disinfectants and spore formation by Clostridium difficile. Lancet 356, 1324 (2000).

  107. 107.

    , , , & Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 63, 520–525 (2009).

  108. 108.

    , , , & Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J. Antimicrob. Chemother. 62, 1078–1085 (2008).

  109. 109.

    et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am. J. Med. 88, 137–140 (1990).

  110. 110.

    et al. Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Infect. Control Hosp. Epidemiol. 19, 333–336 (1998).

  111. 111.

    , , & A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect. Control Hosp. Epidemiol. 19, 494–499 (1998).

  112. 112.

    , , , & Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am. J. Med. 100, 32–40 (1996).

  113. 113.

    , , & Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320, 204–210 (1989).

  114. 114.

    , , & Environmental control to reduce transmission of Clostridium difficile. Clin. Infect. Dis. 31, 995–1000 (2000).

  115. 115.

    et al. Comparison of effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J. Hosp. Infect. 54, 109–114 (2003).

  116. 116.

    et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 54, 168–172 (2004).

  117. 117.

    et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst. Rev. 19, CD003543 (2005).

  118. 118.

    et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg. Infect. Dis. 12, 211–216 (2006).

  119. 119.

    , , , & Impact of a reduction in the use of high risk antibiotics on the course of an epidemic of Clostridium difficile associated disease caused by the hypervirulent NAP1/027 strain. Clin. Infect. Dis. 45, S112–S121 (2007). Useful assessment of the major changes to antimicrobial prescribing that were implemented as part of the control of a large outbreak of CDI caused predominantly by a new virulent C. difficile clone.

  120. 120.

    et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a University hospital using a comprehensive 'bundle' approach. Clin. Infect. Dis. 45, 1266–1273 (2007).

  121. 121.

    , , & Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. Can. Med. Assoc. J. 173, 167–170 (2005); erratum 173, 345 (2005).

  122. 122.

    & Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am. J. Gastroenterol. 102, 201 (2007); author reply 102, 202–204 (2007).

  123. 123.

    Response to the article: McFarland, L. V. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101, 812–822 (2006). Am. J. Gastroenterol. 102, 201–202 (2007).

  124. 124.

    , , , & A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J. Clin. Microbiol. 36, 2240–2247 (1998).

  125. 125.

    et al. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J. Clin. Microbiol. 45, 215–221 (2007).

  126. 126.

    , , , & Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351, 633–636 (1998).

Download references

Acknowledgements

M.R. was supported by EU grant 223585, ERA NET PathoGenoMics grant and ARRS grant J3-0194-0377-08.

Author information

Affiliations

  1. Institute of Public Health Maribor, Centre for Microbiology, Prvomajska 1, 2000 Maribor, Slovenia, and University of Maribor, Faculty of Medicine, Slomaskov trg 15, 2000, Maribor, Slovenia.  maja.rupnik@uni-mb.si

    • Maja Rupnik
  2. Leeds General Infirmary, Leeds, LS1 3EX, UK.  mark.wilcox@leedsth.nhs.uk

    • Mark H. Wilcox
  3. Hines Veterans Affairs Hospital and Loyola University Chicago Stritch School of Medicine, ACOS Research and Development, 5th Avenue and Roosevelt Road, Building 1, Hines, Illinois 60141, USA.  dale.gerding2@med.va.gov

    • Dale N. Gerding

Authors

  1. Search for Maja Rupnik in:

  2. Search for Mark H. Wilcox in:

  3. Search for Dale N. Gerding in:

Competing interests

Dale N. Gerding has received research grants from ViroPharma, Optimer, Merck, GOJO Industries, Cepheid and Massachusetts Biological Laboratories. He is a consultant or advisory board member for ViroPharma, Optimer, Merck, GOJO Industries, Cepheid and BD GeneOhm. He currently holds patents for C. difficile prevention that are licensed to ViroPharma.

Glossary

Pseudomembranous colitis

Found in some (generally the more severe cases) but not all patients with Clostridium difficile infection, and refers to changes on the inner surface of the lining of the large intestine (colon). Characteristically, the colon is inflamed and has visible patches caused by an inflammatory membrane that consists of red and white blood cells, fibrin and bacteria.

Leukocytosis

A term used to refer to an individual with an increased number of white blood cells. A common explanation for leukocytosis is infection, and in general the higher the number of white blood cells (particularly neutrophils) in the blood the greater the severity of the infection.

Toxic megacolon

An uncommon condition that occurs in only the most severe cases of Clostridium difficile infection. The large bowel (colon) becomes dangerously inflamed and dilated, and can eventually perforate.

Ribotype

Characterized by the pattern of amplified intergenic regions in the ribosomal RNA operons present in Clostridium difficile in multiple copies.

Toxinotype

A group of C. difficile strains with identical changes in the toxin-coding region known as the pathogenicity locus (PaLoc).

Heteroresistance

A type of resistance in which some but not all of the cells in a population are resistant to an antibiotic; the remainder retain their susceptibility to the antibiotic.

Negative predictive value

A measurement (usually expressed as a percentage) of all negative test results that are truly negative.

Positive predictive value

A measurement (usually expressed as a percentage) of all positive test results that are truly positive.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrmicro2164

Further reading